drugset / Trial / NCT04674488
TILs for Treatment of Metastatic or Recurrent Cervical Cancer
Phase 0
Unknown
15 enrolled
Shanghai OriginCell Therapeutics Co., Ltd.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · collab
NaSingle-groupOpen-labelTreatment
Summary
Prospective, single center, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent, metastatic cervical carcinoma.
Timeline
- Start
- 2020-12-09
- Primary completion
- 2022-11-09
- Completion
- 2024-11-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TILs | Cell therapy | — | — |
Indications
No indication recorded.